• Source: Tovetumab

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.
This drug was developed by MedImmune, LLC.




References

Kata Kunci Pencarian:

• Tovetumab
• Insulin
• Testosterone
• Dexamethasone
• Amitriptyline
• Trastuzumab deruxtecan
• Cerebrolysin
• Fruquintinib
• Erythropoietin
• Dehydroepiandrosterone